Información de la publicación

Portal del Investigador > Publicaciones > detalle publicacion

Can esketamine save lives? Real-world effectiveness on suicide risk in treatment-resistant depression

Otras comunicaciones del congreso o articulos relacionados con autores/as de la Universidad de Cantabria

A generalisable normative deep learning approach for the discrimination of psychiatric disorders based on neuroanatomy - Comunicación a Congreso
Biomarkers as proxies for cognitive reserve: the role of high density lipoprotein cholesterol in first episode of psychosis - Comunicación a Congreso
Antipsychotic treatment effectiveness in first episode of psychosis-3 open-label randomized clinical trial comparing aripiprazole vs risperidone: analyses of adverse effects after 1-year follow-up - Comunicación a Congreso
Antipsychotic treatment effectiveness in first episode of psychosis-3 open-label randomized clinical trial comparing aripiprazole and risperidone for first-episode psychosis: a long-term effectiveness analysis - Artículo de Revista
A generalizable normative deep learning approach for the discrimination of psychiatric disorders based on neuroanatomy - Comunicación a Congreso
Exploring the cognitive effects of benzodiazepine utilization in a spanish partial hospitalization unit - Comunicación a Congreso
Unveiling persistent negative symptoms in first-episode-psychosis: exploring sociodemographic and diagnostic profiles - Comunicación a Congreso
Gender differences in mental health and hospital emergency department use before suicide in northern Spain: a retrospective study - Comunicación a Congreso
GRIN2B: SNPs and haplotypes association with treatment resistant depression severity and treatment-response to intranasal esketamine - Comunicación a Congreso
Development and validation of a predictive model for early treatment response in first-episode psychosis using clinical and genetic data - Comunicación a Congreso
The slowing puzzle: cytokine clues to processing and psychomotor speed deficits in first-episode of schizophrenia - Comunicación a Congreso
Mantaining clinical improvement with intranasal esketamine in treatment resistant depression - Comunicación a Congreso
Real world multicenter evidence on intranasal esketamine in treatment-resistant depression: from remission to recovery - Comunicación a Congreso

Congreso: ECNP Congress (38º: 2025: Amsterdam)

Editorial: Elsevier B.V.

Año de publicación: 2026

Nº de páginas: 2

Tipo de publicación: Comunicación a Congreso

DOI: 10.1016/j.nsa.2025.105933

ISSN: 2772-4085

Url de la publicación: https://www.sciencedirect.com/science/article/pii/S2772408525005253?via%3Dihub

Leer publicación

Autoría

ANA ISABEL DE SANTIAGO DIAZ

MADRAZO MAZA, M. A.

PAVÓN NAVAJAS, C.

PÉREZ POZA, A.

MESONES PERAL, J. E.

MORA MÍNGUEZ, F.

SÁEZ FUENTES, E.

RODRÍGUEZ BATISTA, F. A.

ARROJO ROMERO, M.

GUTIÉRREZ ROJAS, L.

TORDERA TORDERA, V.

DOMINGOS CHAVES, I.

NÚÑEZ ARIAS, D.

ROSELLÓ MOLINA, V.

MONTES REULA, L.

MIRANDA SIVELO, A.

AROSTEGUI URANGA, S.

Descargar referencia

Bib Ris

Volver

Researchers portal

Portal del personal investigador

Can esketamine save lives? Real-world effectiveness on suicide risk in treatment-resistant depression

Autoría

Descargar referencia